Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Biomarker-Based Score Predicts Poor Outcomes After Acute Ischemic Stroke

Key clinical point: A prognostic score that incorporates copeptin levels, age, recanalization, and stroke risk score has been externally validated and accurately predicts unfavorable outcome, but not mortality, at 3 months.

Major finding: Diagnostic accuracy was 82% for the endpoint of unfavorable functional outcome at 3 months.

Study details: The prognostic score was developed based on a derivation cohort of 319 acute ischemic stroke patients and a validation cohort including another 783 patients in the Copeptin for Risk Stratification in Acute Stroke Patients (CoRisk) Study.

Disclosures: Study authors had nothing to disclose.

Citation:

De Marchis GM et al. AAN 2019, Abstract S47.001